Furthermore, [18F]FEMPA binding to TSPO in HABs increased by an average 19.5% ± 3.0 % in AD patients when compared with controls, suggesting that [18F]FEMPA can detect microglial activation in patients with AD. Here, TSPO is linked to Alzheimer disease.